WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics
This article was originally published in PharmAsia News
Executive Summary
WuXi PharmaTech founder Ge Li has plenty of reasons to feel good these days, despite a widely publicized failed merger with Charles River Laboratories. The largest Chinese pharmaceutical contract research organization not only posted record earnings for the third quarter, it also raised guidance for the full year
You may also be interested in...
From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services
From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia